| 1 |
Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus |
|
|
| Md. Tanvir Kabir, Jannatul Ferdous Mitu, Raushanara Akter, Muhammad Furqan Akhtar, Ammara Saleem, Ahmed Al-Harrasi, Saurabh Bhatia, Md. Sohanur Rahman, Fouad Damiri, Mohammed Berrada, Md. Habibur Rahman |
|
| Environmental Science and Pollution Research. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Perioperative Management of Diabetes in Patients Undergoing Bariatric and Metabolic Surgery: A Narrative Review and The Cleveland Clinic Practical Recommendations |
|
|
| Oscar L. Morey-Vargas, Ali Aminian, Karen Steckner, Keren Zhou, Sangeeta Kashyap, Derrick Cetin, Kevin M. Pantalone, Christopher Daigle, Marcio L. Griebeler, W. Scott Butsch, Robert Zimmerman, Matthew Kroh, Hussein F. Saadi, Danielle Diemer CNP, Bartolome Burguera, Raul J. Rosenthal, M. Cecilia Lansang |
|
| Surgery for Obesity and Related Diseases. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats |
|
|
| Mohammed Fouad Shalaby, Hekma A. Abd El Latif, Mohamed El Yamani, May Ahmed Galal, Sherifa Kamal, Ikhlas Sindi |
|
| Current Therapeutic Research. 2021; 95: 100647 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel |
|
|
| S. Kalra, S. Ghosh, A.K. Das, T. Nair, S. Bajaj, G. Priya, R.N. Mehrotra, S. Das, P. Shah, V. Deshmukh, M. Chawla, D. Sanyal, S. Chandrasekaran, D. Khandelwal, A. Joshi, F. Eliana, H. Permana, M.D. Fariduddin, P.K. Shrestha, D. Shrestha, S. Kahandawa, M. Sumanathilaka, A. Shaheed, A.A. Rahim, A. Orabi, A. Al-ani, W. Hussein, D. Kumar, K. Shaikh |
|
| Indian Heart Journal. 2020; 72(1): 7 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Influence of Bromocriptine Plus Metformin Treatment on Glycaemia and Blood Pressure in Patients with Type 2 Diabetes Mellitus |
|
|
| Alfredo Briones-Aranda, Javier Ramírez-Carballo, Bernardo Alfredo Romero Gómez, Victor Manuel Vega Villa, Manuela Castellanos Pérez, Esmeralda Garcia Parra, Hugo Roberto Santeliz-Montero |
|
| Romanian Journal of Diabetes Nutrition and Metabolic Diseases. 2018; 25(1): 59 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases |
|
|
| Alexander O Shpakov, Kira V Derkach, Lev M Berstein |
|
| Future Science OA. 2015; 1(3) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Antihyperglycemic, Antihyperlipidemic and Cardioprotective Profile of Bromocriptine, Glibenclamide and Metformin Combination in Dexamethasone-induced Hyperglycemic Rats |
|
|
| Adejuwon Adewale Adeneye,Joseph Abayomi Olagunju |
|
| Pharmacologia. 2012; 3(12): 665 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study |
|
|
| |
|
| European Journal of Pharmaceutics and Biopharmaceutics. 2011; |
|
| [HTML Full text] [Google Scholar] [DOI] |
|
| 9 |
Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus |
|
|
| Kerr, J.L., Timpe, E.M., Petkewicz, K.A. |
|
| Annals of Pharmacotherapy. 2010; 44(11): 1777-1785 |
|
| [Pubmed] [Google Scholar] |
|
| 10 |
A systematic account of pathogenesis, diagnosis and pharmacotherapy of metabolic syndrome: Things we need to know |
|
|
| Mahajan, R., Gupta, K., Kapoor, V. |
|
| International Journal of Pharmacology. 2010; 6(4): 430-437 |
|
| [Pubmed] [Google Scholar] |
|
| 11 |
A Systematic Account of Pathogenesis, Diagnosis and Pharmacotherapy of Metabolic Syndrome: Things We Need to Know |
|
|
| R. Mahajan, K. Gupta, V. Kapoor |
|
| International Journal of Pharmacology. 2010; 6(4): 338 |
|
| [HTML Full text] [Google Scholar] [DOI] |
|
